Nathalie Garçon

Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium.

The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris.

Citoxlab France SAS operates as a research laboratory. It offers services in toxicology, genomics, pharmacology, pharmacokinetics, bio-analysis, ecotoxicology, stability testing and regulatory affairs. The company was founded in 1969 and is headquartered in Miserey, France.

TSGH SAS operates as an investment holding company. The company is headquartered in Lyon, France.

bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC.

Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD.

bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

Part of Société Générale SA, Camilla SNC is an investment holding French company. The company is based in Puteaux, France and was founded in 2005.

Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France.

PathoQuest SAS provides diagnostic development services for cancer and infectious diseases. Its services include viral safety testing, adventitious virus detection in cell lines under development and in Master Cell Banks, adventitious virus detection in viral stocks, and identify of the sequences of murine sarcoma virus. The company was founded by Luc Boblet and Marc Eloit on September 14, 2010 and is headquartered in Paris, France.

Sanofi-Aventis France engages in wholesale of pharmaceutical products. The company is headquartered in Gentilly, France.

Indicia Production SASU provides biotechnology research and development services. It manufactures ready-to-use microbiological media for the food and pharmaceutical industry. The company was founded in 1993 and is headquartered in Saint-Genis-l'Argentiere, France.

Lyonbiopôle is a competitiveness cluster located in Lyon, France. The French company serves as a catalyst for the health innovation ecosystem by connecting, developing, and promoting it. Lyonbiopôle's main focus is on the health sector, and it works to ensure that the ecosystem is thriving and innovative.

Based in Lyon within the Center of excellence in Infectious Diseases, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays. Platine actively supports the development of in-vitro diagnostic, cosmetic and therapeutic product candidates, highlighting key markers and features in both normal and pathological conditions, and guiding decisions at each development stage. Using state-of-the-art technologies such as multi-parametric flow cytometry, Singulex, Luminex, Mesoscale Discovery, ELISpot or ELISA, Platine Pharma Services offers a fit-for-purpose approach to its customers and partners.

Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. engages in theresearch and development, and manufacture of immunotherapies for the treatment of oncology and infectious diseases. Its business scope includes biopharmaceutical technology development, technology transfer, and related technical advisory services. The company was founded on July 26, 2010 and is headquartered in Tianjin, China.

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

Transcure Bioservices SAS provides research and development platforms service. It offer services to pharmaceutical, biotech, start-up, and academic researchers who need solutions for drug profiling and development. The company was founded on June 07, 2012 and is headquartered in Archamps, France.

MabDesign Association is a French biotherapy industry association that aims to structure the biopharmaceutical industry from its R&D phases to biomanufacturing and marketing. The private company is based in Lyon, France and was founded in 2014. The association offers services to help companies strengthen their competitiveness and implement a solid intellectual property strategy. MabDesign's board of directors is composed of a pharmaceutical industry college and a competitiveness cluster college. The CEO is Nicolas Groux.

Indicia Participations functions as an investment holding French company. The private company is based in Saint-Genis-l'Argentière, France.

SCI CALIFORNIE is a French company that leases real estate properties.

H-Immune SAS engages in biotechnology research activities. It develops medicine and pharmaceutical products. The company was founded on October 17, 2016 and is headquartered in Paris, France.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist.

Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison.